- Projects & figures
- News & Events
- Managing your project
- About ERC
ELECTION SERIES #3
The traditional pencil-and-paper method to mark your vote in the polling booth has been gradually replaced by electronic voting machines in many countries, in Europe and beyond. Ensuring the security of electronic voting machines and quelling fears of vote-rigging have become ever more important. One ERC-funded researcher has been working tirelessly to develop such an e-voting system through two projects, SEEVS and its follow-up SEEVCA.
Tamoxifen, a drug used in breast cancer treatment, may be repositioned to treat pancreatic cancer
Pancreatic cancer is the 4th leading cause of death by cancer in Europe. It has a very low survival rate with less than 1 per cent of sufferers surviving for 10 or more years. Over the last 40 years the survival rate has not significantly changed and finding an effective therapy has become a pressing challenge in cancer research. A team based at Imperial College London led by Armando Del Río Hernández, has now demonstrated that a well-known drug could be effective to fight this deadly and other forms of cancer, such as liver cancer.
The increasing development of wearable technology sparks the need for new, innovative ways to interact with our shiny gadgets. Deviating from the conventional approach based on touch-sensitive devices, Prof. Jürgen Steimle aims at producing body-worn user interfaces that can be applied directly on the skin. Highly personalised, biocompatible and ultrathin, these devices will seamlessly blend with the human skin to create a technological extension of our body.
The amount of currently available biomedical data is overwhelming. Large databases exist at different scales, from genes, to proteins, to patients' histories. But what do scientists do with all this information? Serbian-born Professor Nataša Pržulj, from University College London, works with Big Data to establish patterns and gain knowledge that could revolutionise how we treat diseases.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
Travellers already benefit from applications harnessing data from sensor networks and smartphone users. They calculate alternative routes, help plan carpooling routes, or support the optimisation of public transport. With her ERC grant, Prof. Vana Kalogeraki works on a comprehensive software framework that will simplify the development of such mobile human-centred systems and make them more predictable and reliable.
Is a precise answer always better than a slightly less detailed one? Not necessarily. Some problems could take forever to compute and tie up vast IT capacity. Where solutions are needed urgently, e.g. in business or manufacturing, near-enough can be more than enough. ERC-funded research has produced a library of fast, powerful approximation algorithms.
We are nowadays in the middle of the second quantum revolution. The first one brought forward the rules that govern physics at the atomic level – the quantum mechanics. The second entails the use of these rules for developing new technologies. In his ERC-funded project, Prof. Andris Ambainis from the University of Latvia investigates new methods of developing quantum algorithms and the limits of quantum computing.
Tired of endlessly looking for a parking spot? Dreaming of having a bird's-eye view to locate free spaces in a congested city? ERC grantee Prof Luc Van Gool is a research leader in the area of computer vison. With his project "VarCity", he works to innovate existing 3D city modelling by using object class recognition methods and crowd generated data. To apply his idea, Prof. Van Gool received an additional ERC Proof of Concept grant and created a spin-off that commercialises a video-based smart parking system. In the city of Locarno, Switzerland, "Parquery" stands the test.
Dr Málnási-Csizmadia focuses on enzymes, proteins essential for body functions, and the largely unexplored intricate mechanisms underlying their activity. His recent findings could open the way to a ground-breaking development in pharmacology, especially in targeted cancer therapy.